focused on the development and commercialization of radiopharmaceutical theranostics and automated synthesizer & functional modules for radiopharmaceutical production in both R&D and GMP settings.

Founded in July 2021, NORROY has developed more than 7 pipelines currently under clinical investigations for urological cancers, gastrointestinal & pancreatic cancers, lung cancers, breast & ovarian cancers, nasopharyngeal cancers, neurological cancers, and solid tumors. In addition to innovation of pipelines and automated modules, NORROY also continues to establish a solid global supply of multiple radioisotopes, build commercial GMP manufacturing facilities and global distribution network with international partners.

Up to date, NORROY has received 4 IND approvals from the U.S. Food and Drug Administration (FDA), and 4 IND approvals from the China National Medical Products Administration (NMPA), and works closely with the regulatory agencies to advance its late-stage pipelines through internationally registered clinical trial investigations.